Paroxysmal non-kinesigenic dyskinesia in antiphospholipid syndrome
Marc Engelen MD
Department of Neurology, Academic Medical Centre, Amsterdam, The Netherlands
Search for more papers by this authorCorresponding Author
Marina A.J. Tijssen MD, PhD
Department of Neurology, Academic Medical Centre, Amsterdam, The Netherlands
Department of Neurology H2-222, Academic Medical Centre, PO Box 22660, 1100 DD Amsterdam, The NetherlandsSearch for more papers by this authorMarc Engelen MD
Department of Neurology, Academic Medical Centre, Amsterdam, The Netherlands
Search for more papers by this authorCorresponding Author
Marina A.J. Tijssen MD, PhD
Department of Neurology, Academic Medical Centre, Amsterdam, The Netherlands
Department of Neurology H2-222, Academic Medical Centre, PO Box 22660, 1100 DD Amsterdam, The NetherlandsSearch for more papers by this authorAbstract
We report on a patient with a mixed movement disorder classifiable as a paroxysmal nonkinesigenic dyskinesia, occurring as the first manifestation of primary antiphospholipid syndrome (PAPS). Possible pathophysiology is discussed based on recent literature, and we stress that PAPS must be considered in movement disorders of a paroxysmal nature. © 2004 Movement Disorder Society
Supporting Information
This article includes Supplementary Video, available online at www.interscience.wiley.com/jpages/0885-3185/suppmat
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunological manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019–1027.
- 2 Durrani OM, Gordon C, Murray PI. Primary anti-phospholipid antibody syndrome (PAPS): current concepts. Surv Ophthalmol 2002; 47: 215–238.
- 3 Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHWM, Machin SJ, Barquinero J, Outt HH. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine 1989; 68: 366–374.
- 4 Furie R, Ishikawa T, Dhawan V, Eidelberg D. Alternating hemichorea in primary antiphospholipid syndrome. Neurology 1994; 44: 2197–2199.
- 5 Sundén-Cullberg J, Tedroff J, Aquilonius SM. Reversible chorea in primary antiphospholipid syndrome. Mov Disord 1998; 13: 147–149.
- 6 Masala C, Morino S, Zangari P, Antonini G. Chorea in primary antiphospholipid syndrome. Clin Neurol Neurosurg 1996; 98: 247–248.
- 7 Nordal EB, Nielsen J, Marhaug G. Chorea in juvenile primary antiphospholipid syndrome. Scand J Rheumatol 1999; 28: 324–327.
- 8 Bhatia KP. The paroxysmal dyskinesias. J Neurol 1999; 246: 149–155.
- 9 Blakeley J, Jankovic J. Secondary causes of paroxysmal dyskinesia. In: S Fahn, editor. Myoclonus and paroxysmal dyskinesias. Philadelphia: Lippincott Williams and Wilkins; 2002. p 401–420.
- 10 Leys D, Destee A, Petit H, Warot P. Chorea associated with oral contraception. J Neurol 1987; 235: 46–48.
- 11 Miranda M, Cardoso F, Giovannoni G, Church A. Oral contraceptive induced chorea: another condition associated with anti-basal ganglia antibodies. J Neurol Neurosurg Psychiatry 2004; 75: 327–328.
- 12 Iskander MK, Khan M. Chorea as the initial presentation of oral contraceptive related systemic lupus erythematosus. J Rheumatol 1989; 16: 850–851.
- 13 Omdal R, Roalso S. Chorea gravidarum and chorea associated with oral contraception—diseases due to antiphospholipid antibodies? Acta Neurol Scand 1992; 86: 219–220.
- 14 Cervera R, Asherson RA, Lie JT. Clinicopathologic correlations of the antiphospholipid syndrome. Semin Arthritis Rheum 1995; 24: 262–272.
- 15 Sun SS, Liu FY, Tsai JJP, Yen RF, Kao CH, Huang WS. Using 99mTc HMPAO brain SPECT to evaluate the effects of anticoagulant therapy on regional cerebral blood flow in primary antiphospholipid antibody syndrome patients with brain involvement—a preliminary report. Rheumatol Int 2003; 23: 301–304.
- 16 Brey RL, Gharavi AE, Lokshin MD. Neurologic complications of antiphospholipid antibodies. Rheum Dis Clin North Am 1993; 19: 833–850.
- 17 Piccolo I, Defanti CA, Soliveri P, Volontè MA, Cislaghi G, Girotti F. Cause and course in a series of patients with spontaneous chorea. J Neurol 2003; 250: 429–435.
- 18 Lee PH, Nam HS, Lee KY, Lee BI, Lee JD. Serial brain SPECT images in a case of Sydenham chorea. Arch Neurol 1999; 56: 237–240.
- 19 Heye N, Jergas M, Hötzinger H, Farahati J, Pöhlau D, Przuntek H. Sydenham chorea: clinical, EEG, MRI and SPECT findings in the early stage of disease. J Neurol 1993; 240: 121–123.
- 20 Giedd JN, Rapoport JL, Kruesi MJ, Parker C, Schapiro MB, Allen AJ, Leonard HL, Kaysen D, Dickstein DP, Marsh WL. Sydenham's chorea: magnetic resonance imaging of the basal ganglia. Neurology 1995; 45: 2199–2202.
- 21 Goldman S, Amrom D, Sliwowski HB, Detemmerman D, Goldman S, Bidaut LM, Stanus E, Luxen A. Reversible striatal hypermetabolism in a case of Sydenham's chorea. Mov Disord 1993; 8: 355–358.
- 22 Paus S, Pötzsch B, Risse JH, Klockgether T, Wüllner U. Chorea and antiphospholipid antibodies: treatment with methotrexate. Neurology 2000; 56: 137.
